Nitazoxanide: a new broad spectrum antiparasitic agent - PubMed (original) (raw)
Review
Nitazoxanide: a new broad spectrum antiparasitic agent
Clinton A White Jr. Expert Rev Anti Infect Ther. 2004 Feb.
Abstract
Nitazoxanide (Alinia, Romark Laboratories) was synthesized based on the structure of niclosamide. In vitro studies have demonstrated activity against a broad range of parasites as well as some bacteria. Three controlled trials demonstrated efficacy in cryptosporidiosis, however, the efficacy in advanced AIDS patients (CD4 cell counts = 50) at approved doses was limited. Trials have also demonstrated efficacy comparable to metronidazole (Flagyl, GD Searle and Co.) in giardiasis with fewer side effects. Nitazoxanide is also effective versus intestinal helminths and tapeworms as well as in chronic fascioliasis. Side effects in clinical trials have been similar to placebo. Nitazoxanide is the first agent proven to be effective in cryptosporidiosis. It has also proven efficacy in giardiasis. Nitazoxanide is efficacious again intestinal helminths. Additional indications may be developed in the future.
Similar articles
- Nitazoxanide: an important advance in anti-parasitic therapy.
White AC Jr. White AC Jr. Am J Trop Med Hyg. 2003 Apr;68(4):382-3. Am J Trop Med Hyg. 2003. PMID: 12875283 No abstract available. - Cryptosporidium and Giardia: treatment options and prospects for new drugs.
Rossignol JF. Rossignol JF. Exp Parasitol. 2010 Jan;124(1):45-53. doi: 10.1016/j.exppara.2009.07.005. Epub 2009 Jul 24. Exp Parasitol. 2010. PMID: 19632225 - Epidemiology and control of intestinal parasites with nitazoxanide in children in Mexico.
Diaz E, Mondragon J, Ramirez E, Bernal R. Diaz E, et al. Am J Trop Med Hyg. 2003 Apr;68(4):384-5. Am J Trop Med Hyg. 2003. PMID: 12875284 - Nitazoxanide treatment for giardiasis and cryptosporidiosis in children.
Bailey JM, Erramouspe J. Bailey JM, et al. Ann Pharmacother. 2004 Apr;38(4):634-40. doi: 10.1345/aph.1D451. Epub 2004 Feb 27. Ann Pharmacother. 2004. PMID: 14990779 Review. - Nitazoxanide: a review of its use in the treatment of gastrointestinal infections.
Anderson VR, Curran MP. Anderson VR, et al. Drugs. 2007;67(13):1947-67. doi: 10.2165/00003495-200767130-00015. Drugs. 2007. PMID: 17722965 Review.
Cited by
- Broad-spectrum therapeutics: A new antimicrobial class.
Firth A, Prathapan P. Firth A, et al. Curr Res Pharmacol Drug Discov. 2021;2:100011. doi: 10.1016/j.crphar.2020.100011. Epub 2020 Dec 11. Curr Res Pharmacol Drug Discov. 2021. PMID: 34870144 Free PMC article. Review. - Synergistic effect of nitazoxanide with neuraminidase inhibitors against influenza A viruses in vitro.
Belardo G, Cenciarelli O, La Frazia S, Rossignol JF, Santoro MG. Belardo G, et al. Antimicrob Agents Chemother. 2015 Feb;59(2):1061-9. doi: 10.1128/AAC.03947-14. Epub 2014 Dec 1. Antimicrob Agents Chemother. 2015. PMID: 25451059 Free PMC article. - Clostridium difficile infection: Updates in management.
Tariq R, Khanna S. Tariq R, et al. Indian J Gastroenterol. 2017 Jan;36(1):3-10. doi: 10.1007/s12664-016-0719-z. Epub 2016 Dec 20. Indian J Gastroenterol. 2017. PMID: 27995486 Review. - Nitazoxanide inhibits acetylated KLF5-induced bone metastasis by modulating KLF5 function in prostate cancer.
Huang Q, Liu M, Zhang D, Lin BB, Fu X, Zhang Z, Zhang B, Dong JT. Huang Q, et al. BMC Med. 2023 Feb 21;21(1):68. doi: 10.1186/s12916-023-02763-4. BMC Med. 2023. PMID: 36810084 Free PMC article. - In Vitro Evaluation of Novel Nitazoxanide Derivatives against Mycobacterium tuberculosis.
Odingo J, Bailey MA, Files M, Early JV, Alling T, Dennison D, Bowman J, Dalai S, Kumar N, Cramer J, Masquelin T, Hipskind PA, Parish T. Odingo J, et al. ACS Omega. 2017 Sep 30;2(9):5873-5890. doi: 10.1021/acsomega.7b00892. Epub 2017 Sep 18. ACS Omega. 2017. PMID: 30023755 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Research Materials